25
20
15
10
5
0
No itch
Mild itch
CS itch
CS threshold
25
20
15
10
5
0
No itch
Mild itch
CS itch
CS threshold
10
0
% of all patients (n=211)
20
30
40
50
60
70
80
CS itch*
10
0
% of all patients (n=211)
20
30
40
50
60
70
80
CS itch*
a
p
r
u
60
%
n = 21
20
%
n = 7
22
%
n = 17
9
%
n = 3
1
1
%
n = 4
8
%
n = 6
1
1
%
n = 4
9
%
n = 3
3
%
n = 2
3
1
%
n = 11
6
7
%
n = 51
4
9
%
n = 17
a
p
r
u
60
%
n = 21
20
%
n = 7
22
%
n = 17
9
%
n = 3
1
1
%
n = 4
8
%
n = 6
1
1
%
n = 4
9
%
n = 3
3
%
n = 2
3
1
%
n = 11
6
7
%
n = 51
4
9
%
n = 17
14
12
10
8
6
4
2
0
No itch
Mild itch
CS itch
CS threshold
14
12
10
8
6
4
2
0
No itch
Mild itch
CS itch
CS threshold
50
40
30
20
10
0
No itch
Mild itch
CS itch
CS threshold
50
40
30
20
10
0
No itch
Mild itch
CS itch
CS threshold
6
4
-2
2
0
-4
-6
-8
-8
-6
-4
-2
0
2
4
6
r=0.84
p<0.0001
Change from baseline in MSS
Change from baseline in MIS
6
4
-2
2
0
-4
-6
-8
-8
-6
-4
-2
0
2
4
6
r=0.84
p<0.0001
Change from baseline in MSS
Change from baseline in MIS
N
u
m
b
er
o
f
p
atie
n
t
s
1
2
0
1
00
80
60
40
2
0
0
F
emal
e
, n
(
%
)
A
ge
(
media
n
, Q
1
–
Q
3
)
A
L
P
(
media
n
, Q
1
–
Q
3
)
Cirrhosi
s
, n
(
%
)
D
e
compensate
d
, n
(
%
)
5
9
(
9
4
)
58
(
5
2
–
6
4
)
1
7
7
(
1
3
3
–
2
8
4
)
3
0
(
4
8
)
18
(
6
0
)
9
7
(
9
1
)
6
4
(
5
5
–
7
1
)
1
43
(
11
6
–
1
8
7
)
2
9
(
2
7
)
7
(
2
4
)
3
8
(
9
3
)
6
4
(
5
6
–
7
1
)
153
(
1
2
6
–
22
8
)
15
(
3
7
)
5
(
3
3
)
N
u
m
b
er
o
f
p
atie
n
t
s
1
2
0
1
00
80
60
40
2
0
0
F
emal
e
, n
(
%
)
A
ge
(
media
n
, Q
1
–
Q
3
)
A
L
P
(
media
n
, Q
1
–
Q
3
)
Cirrhosi
s
, n
(
%
)
D
e
compensate
d
, n
(
%
)
5
9
(
9
4
)
58
(
5
2
–
6
4
)
1
7
7
(
1
3
3
–
2
8
4
)
3
0
(
4
8
)
18
(
6
0
)
9
7
(
9
1
)
6
4
(
5
5
–
7
1
)
1
43
(
11
6
–
1
8
7
)
2
9
(
2
7
)
7
(
2
4
)
3
8
(
9
3
)
6
4
(
5
6
–
7
1
)
153
(
1
2
6
–
22
8
)
15
(
3
7
)
5
(
3
3
)
<6 hours
6–12 hours
12–18 hours
18–23 hours
All day
5-D ITCH: DURATION
a
0–2 body parts
3–5 body parts
6–10 body parts
11–13 body parts
14–16 body parts
5-D ITCH: DISTRIBUTION
b
Legend
<6 hours
6–12 hours
12–18 hours
18–23 hours
All day
5-D ITCH: DURATION
a
0–2 body parts
3–5 body parts
6–10 body parts
11–13 body parts
14–16 body parts
5-D ITCH: DISTRIBUTION
b
Legend
Fatigue
Symptoms
Emotional
No Itch
Clinically Significant Itch
Fatigue
Symptoms
Emotional
No Itch
Clinically Significant Itch
10.0
7.5
5.0
2.5
0.0
Pruritus intensity in the past 7 days
(‘current pruritus’ NRS)
2011
2014
2017
Survey year
Archetypal disease patterns (n = 1753)
Persistent low
pruritus group (54%)
Persistent moderate
pruritus group (28%)
Persistent high
pruritus group (18%)
10.0
7.5
5.0
2.5
0.0
Pruritus intensity in the past 7 days
(‘current pruritus’ NRS)
2011
2014
2017
Survey year
Archetypal disease patterns (n = 1753)
Persistent low
pruritus group (54%)
Persistent moderate
pruritus group (28%)
Persistent high
pruritus group (18%)
0
No itch
≥1 to <7
Mild itch
a
≥7
Clinically
significant itch
b
40
35
30
25
20
15
10
5
0
PBC-40 domain score​
0
No itch
≥1 to <7
Mild itch
a
≥7
Clinically
significant itch
b
40
35
30
25
20
15
10
5
0
PBC-40 domain score​
Fatigue
Social
Symptoms
Cognitive
Emotional
Itch
Domain
Fatigue
Social
Symptoms
Cognitive
Emotional
Itch
Domain
Symptom measure
scores (range)
11–54
8–47
6–33
6–29
3–14
0–15
Symptom measure
scores (range)
11–54
8–47
6–33
6–29
3–14
0–15
40
30
20
10
0
No itch
Mild itch
CS itch
CS threshold
40
30
20
10
0
No itch
Mild itch
CS itch
CS threshold
25
20
15
10
5
0
No itch
Mild itch
CS itch
CS threshold
25
20
15
10
5
0
No itch
Mild itch
CS itch
CS threshold
42
42
37
%
37
%
81
%
81
%
37
%
37
%
81
%
81
%
RESULTS
RESULTS